by Carolyn Haywood | Aug 11, 2023 | EPO
Background to the referral The referral comes from Board 3.3.03 in the consideration of T 0438/19, an appeal against the decision of the opposition division to reject an opposition against European patent no. 2626911 directed to a material for encapsulating a solar...
by David Eyre | May 25, 2023 | EPO
In laboratory practice the production of new antibodies is now often considered routine with a desired epitope synthesised and used to raise antibodies to that specific sequence. Accordingly under European practice the EPO views generating antibodies against any known...
by David Eyre | Feb 28, 2023 | UK
In this decision the Hearing Officer noted that a marketing authorisation is focused on what a product is rather than what it does. Consequently, a change in how the authorised product is used does not alter the basis of the original marketing authorisation....
by David Eyre | Sep 6, 2022 | UK
In the case of Neurim and Flynn v Mylan [2022] EWCA Civ 699 The Court of Appeal has issued a decision finding that the plausibility of a therapeutic effect can be demonstrated using subjective data obtained by questioning the users of a pharmaceutical product....
by Eddie Bishop | Apr 25, 2022 | US & International
Questions on the European SPC Regulation, in particular in relation to SPCs for combination products, have been raised at the CJEU many times over the years. It is therefore hoped that this newest referral may provide some much-needed clarity. Background For an SPC to...
Recent Comments